SC
BMRN icon

Scotia Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Scotia Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-10,164
Closed -$714K – 578
2013
Q4 		$714K Buy
+10,164
New +$690K 0.02% 313

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Winslow Capital Management
Winslow Capital Management Minneapolis, Minnesota $29.1B AUM 43.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Scotia Capital's BMRN Position: Q1 2014 in Review

Scotia Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2014, closing a stake of 10,164 shares — an estimated $714K sold.

Scotia Capital first reported a position in BMRN in Q4 2013 and held it in 1 quarter. The position peaked at $714K in Q4 2013. 313 funds tracked by Wall St. Rank hold BMRN as of Q1 2014.

  • Scotia Capital reported no remaining BioMarin Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Scotia Capital sold 10,164 BioMarin Pharmaceuticals shares in Q1 2014, an estimated $714K.
  • Scotia Capital first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • Scotia Capital's BioMarin Pharmaceuticals position peaked at $714K in Q4 2013.
  • 313 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2014.

Based on Scotia Capital's 13F filing for Q1 2014, filed 14 May 2014.